Laboratory equipment company Thermo Fisher Scientific Inc (TMO.N) agreed to acquire private-equity owned Phadia, maker of allergy and autoimmune tests, for about $3.5 billion to expand in specialty diagnostics. Thermo said on Thursday that the deal to purchase Sweden-based Phadia from European private equity firm Cinven would immediately add to earnings. The deal is expected to be completed in the fourth quarter and add 26 to 30 cents per share to 2012 earnings.
Thermo Fisher Scientific Inc. (Thermo Fisher) is engaged in serving science. Shares of TMO remained unchanged at $62.74. In the past year, the shares have traded as low as $41.74 and as high as $63.29. On average, 3034550 shares of TMO exchange hands on a given day and today's volume is recorded at 0.
Source
